The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Open accessAbstract
This study investigated the effects of rimonabant (SR141716), an antagonist of the cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis and related features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis factor alpha [TNFα]), dyslipidemia, and reduced plasma levels of adiponectin. We report that oral treatment of obese (fa/fa) rats with rimonabant (30 mg/kg) daily for 8 weeks abolished hepatic steatosis. This treatment reduced hepatomegaly, reduced elevation of plasma levels of enzyme markers of hepatic damage (alanine aminotransferase, gamma glutamyltransferase, and alkaline phosphatase) and decreased the high level of local hepatic TNFα currently associated with steatohepatitis. In parallel, treatment of obese (fa/fa) rats with rimonabant reduced the high plasma level of the proinflammatory cytokine TNFα and increased the reduced plasma level of the anti-inflammatory hormone adiponectin. Finally, rimonabant treatment also improved dyslipidemia by both decreasing plasma levels of triglycerides, free fatty acids, and total cholesterol and increasing the HDLc/LDLc ratio. All the effects of rimonabant found in this study were not or only slightly observed in pair-fed obese animals, highlighting the additional beneficial effects of treatment with rimonabant compared to diet. These results demonstrate that rimonabant plays a hepatoprotective role and suggest that this CB1 receptor antagonist potentially has clinical applications in the treatment of obesity-associated liver diseases and related features of metabolic syndrome. (HEPATOLOGY 2007.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., & Spiegelman, B. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117936 · Cited by 3,543
Adiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
Adipokines: inflammation and the pleiotropic role of white adipose tissue
Trayhurn, P., & Wood, I. S. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041213 · Cited by 2,210
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170
Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,773
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Obesity, Metabolic Syndrome, and Cardiovascular Disease
Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0372 · Cited by 1,371
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ
Trayhurn, P., & Beattie, J. H. (2001) · Proceedings of the Nutrition Society · doi:10.1079/pns200194 · Cited by 1,259
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Minireview: The Adipocyte—At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis
Rajala, M. W., & Scherer, P. E. (2003) · Endocrinology · doi:10.1210/en.2003-0580 · Cited by 1,190
Obesity, Weight Gain, and the Risk of Kidney Stones
Taylor, E. N. (2005) · JAMA · doi:10.1001/jama.293.4.455 · Cited by 1,162
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice
Okamoto, Y., Kihara, S., Ouchi, N., Nishida, M., Arita, Y., Kumada, M., Ohashi, K., Sakai, N., Shimomura, I., Kobayashi, H., et al. (2002) · Circulation · doi:10.1161/01.cir.0000042707.50032.19 · Cited by 1,030
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948
Adiponectin as a Biomarker of the Metabolic Syndrome
Ryo, M., Nakamura, T., Kihara, S., Kumada, M., Shibazaki, S., Takahashi, M., Nagai, M., Matsuzawa, Y., & Funahashi, T. (2004) · Circulation Journal · doi:10.1253/circj.68.975 · Cited by 767
Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function
Goldstein, B. J., & Scalia, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0518 · Cited by 647
Arnone, M., Maruani, J., Chaperon, F., Thiébot, M.-H., Poncelet, M., Soubrié, P., & Fur, G. L. (1997) · Psychopharmacology · doi:10.1007/s002130050326 · Cited by 594
Self-citationBensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Self-citationAnti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 566
Self-citationDecreased Plasma Adiponectin Concentrations in Women with Dyslipidemia
Matsubara, M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2764 · Cited by 544
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00322-1 · Cited by 487
Adiponectin and cancer: a systematic review
Kelesidis, I., Kelesidis, T., & Mantzoros, C. S. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603051 · Cited by 487
Tomita, K., Tamiya, G., Ando, S., Ohsumi, K., Chiyo, T., Mizutani, A., Kitamura, N., Toda, K., Kaneko, T., Horie, Y., et al. (2006) · Gut · doi:10.1136/gut.2005.071118 · Cited by 438
Model of nonalcoholic steatohepatitis
Lieber, C. S., Leo, M. A., Mak, K. M., Xu, Y., Cao, Q., Ren, C., Ponomarenko, A., & DeCarli, L. M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.502 · Cited by 424
The evolving role of inflammation in obesity and the metabolic syndrome
Lee, Y.-H., & Pratley, R. E. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0071-7 · Cited by 369
The Role of TNF-α in Insulin Resistance
Borst, S. E. (2004) · Endocrine · doi:10.1385/endo:23:2-3:177 · Cited by 369
Chaperon, F., Soubrié, P., Puech, A. J., & Thiébot, M.-H. (1998) · Psychopharmacology · doi:10.1007/s002130050518 · Cited by 280
Self-citationHepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models
den Boer, M., Voshol, P. J., Kuipers, F., Havekes, L. M., & Romijn, J. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000116217.57583.6e · Cited by 260
A Novel Pathway to the Manifestations of Metabolic Syndrome
Sonnenberg, G. E., Krakower, G. R., & Kissebah, A. H. (2004) · Obesity Research · doi:10.1038/oby.2004.24 · Cited by 257
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., & Vettor, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01821 · Cited by 256
Adiponectin and its role in the obesity-induced insulin resistance and related complications.
Haluzík, M., Pařízková, J., & Haluzík, M. (2004) · Physiological Research · doi:10.33549/physiolres.930479 · Cited by 247
Cytokines and the pathogenesis of non-alcoholic steatohepatitis
Diehl, A. M., Li, Z. P., Lin, H. Z., & Yang, S. Q. (2005) · Gut · doi:10.1136/gut.2003.024935 · Cited by 216
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile
Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00374.x · Cited by 203
Self-citationDiagnosis, prevention, and intervention for the metabolic syndrome
Scott, C. L. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00507-1 · Cited by 191
Gary‐Bobo, M., Elachouri, G., Scatton, B., Fur, G. L., Oury-Donat, F., & Bensaïd, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015040 · Cited by 160
Self-citationWhite adipose tissue and cardiovascular disease
Matsuzawa, Y. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.001 · Cited by 122
Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship?
Bugianesi, E., Zannoni, C., Vanni, E., Marzocchi, R., & Marchesini, G. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.12.008 · Cited by 92
Obesity, Insulin Resistance and Cancer Risk
Jee, S. H., Kim, H. J., & Lee, J. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.4.449 · Cited by 90
The endocannabinoid system and the treatment of obesity
Pagotto, U., Vicennati, V., & Pasquali, R. (2005) · Annals of Medicine · doi:10.1080/07853890510037419 · Cited by 85
Adiponectin: linking the metabolic syndrome to its cardiovascular consequences
Rabin, K. R., Kamari, Y., Avni, I., Grossman, E., & Sharabi, Y. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.465 · Cited by 47
Adiponectin as a protective factor in hepatic steatosis
Méndez-Sánchez, N. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i12.1737 · Cited by 45
Importance and Management of Dyslipidemia in the Metabolic Syndrome
Menuet, R., Lavie, C. J., & Milani, R. V. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00007 · Cited by 34
Patent focus on new anti-obesity agents: September 1999 - February 2000
Carpino, P. A. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.6.819 · Cited by 11
Nonalcoholic fatty liver disease: a review
Poordad, F. F. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.661 · Cited by 4
Cited by
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
The endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Non-alcoholic fatty liver disease: The mist gradually clears
de Alwis, N. M. W., & Day, C. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.009 · Cited by 603
Metadata
- Authors
- Gary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., Arnone, M., Croci, T., Soubrié, P., Oury-Donat, F., Maffrand, J. P., Scatton, B., Lacheretz, F., Le Fur, G., Herbert, J. M., & Bensaid, M.
- Venue
- Hepatology
- Published
- 2007-07
- Volume
- 46
- Issue
- 1
- Pages
- 122-129
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1985390176
- Cited by
- 304
- References
- 49
- FWCI
- 29.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.